| 1Q 2019

Valuation Metrics in Emerging Debt: 1Q 2019

Executive Summary

In last quarter’s publication we highlighted significant value in emerging external debt, with local debt markets looking to be on the attractive end of a neutral zone. As it happened, the EMBIG hard currency index rose 6.6% for the quarter and the GBI-EMGD local benchmark returned 2.9%. Three themes for the quarter are worth highlighting: 1) the markets have effectively established that the Fed has turned dovish and the hiking cycle is temporarily or permanently stalled; 2) trade tensions moderated with a postponement of U.S. tariffs on China, as talks proceeded; and 3) global economic growth forecasts have been revised down, for both developed and emerging economies. Rightly or wrongly, the market placed relatively more importance on the first two than the third.

As we enter the second quarter, our valuation metrics for emerging external debt are less compelling than they were at the beginning of the year, due to the rally. The asset class looks to be on the cusp of neutral to cheap. This is also how we would currently describe local market emerging debt. Emerging currencies remain at the cheap end of our neutral range. As for local rates, first quarter moves resulted in increased attractiveness of emerging. Emerging real yields rose as a result of inflation moderation, while G-3 real yields fell. Thus, the EM-DM real yield differential moved in favor of emerging, now standing at around 200 bps.

In this piece, we update our valuation charts, and provide our readers with some small changes in methodology that we have adopted (See the Appendix for more detail).

Download to read the full article.

Disclaimer: The views expressed are the views and understanding of Carl Ross and Victoria Courmes through the period ending March 2019 and are subject to change at any time based on market and other conditions. While all reasonable effort has been taken to insure accuracy, no representation or warranty for accuracy is provided nor should be assumed. This is not an offer or solicitation for the purchase or sale of any security and should not be construed as such. References to specific securities and issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities.
Copyright © 2019 by GMO LLC. All rights reserved.
Subscribe to GMO Research